January 18, 2011
CASE CCC IN THE NEWS
Breakthroughs & Advances
MESSAGE FROM THE DIRECTOR
Brian J. Bolwell, MD Appointed Associate Director for the Taussig Cancer Institute
Stan Gerson, MD, Director of the Case Comprehensive Cancer Center, announces the appointment of Brian J. Bolwell, MD as Associate Director for the Taussig Cancer Institute. Dr. Bolwell will join the senior leaders of the Cancer Center coordinating the overall cancer research effort of the 364 members of the Cancer Center who are faculty at CWRU, University Hospitals, and Cleveland Clinic.
In his position as Associate Director, Dr. Bolwell oversees the clinical research at the Taussig Cancer Institute and facilitates its coordination and integration with the scientific programs and clinical investigations taking place throughout the Cancer Center. Major elements of the clinical research program are efforts to increase investigator initiated clinical trials, overall accrual to clinical trials, and translational research with the basic science laboratories of the Taussig Cancer Institute.
Dr. Bolwell brings a wealth of experience to his current position. He received his BA from Harvard University and his medical degree from the CWRU School of Medicine. Following his internship and residency at University Hospitals of Cleveland, he did his fellowship in hematology and medical oncology at the Hospital of the University of Pennsylvania in Philadelphia. Dr. Bolwell joined the faculty of the Cleveland Clinic in 1987, became the director of the bone marrow transplant program in 1988, and joined the Cleveland Clinic Board of Governors in 2004. Dr. Bolwell has served as Chairman of the Department of Hematologic Oncology and Blood Disorders since 2006, and Vice Chief of Staff since 2009. He is Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and has been a member of the Case Comprehensive Cancer Center since its expansion to include the Cleveland Clinic in 2003. He has published approximately 150 papers in the areas of transplantation and hematologic malignancies, and is active in the clinical research programs in transplantation within the Stem Cell Program of the Cancer Center.
Clifford Harding, MD, PhD, Named Chair of Pathology at CWRU School of Medicine and UHCMC
Congratulations to Dr. Clifford Harding, who was recently named Chair of Pathology at the CWRU School of Medicine and UHCMC. Dr. Harding became the Interim Chair of the department in May 2008, and assumed his new post as Department Chair in late December. We wish Dr. Harding continued success in his position.
MARK YOUR CALENDARS
Breast Cancer Retreat
The Cancer Center Breast Cancer Retreat is scheduled for Wednesday, February 9 at 9 am in the George S. Dively Building, Room 214. Further details and retreat agenda will be posted soon.
Cancer Research Institute Investigator Award
The Cancer Research Institute (CRI) is accepting applications for its Investigator Award, which supports accomplished assistant professors undertaking their first independent investigations in cancer immunology or general immunology. Candidates for the investigator award must hold a doctoral degree and be a tenure-track Assistant Professor at the time of award activation. CRI has no citizenship restrictions, and research supported by the award may be conducted at medical schools and research centers in the United States or abroad.
Deadline: March 1
Interinstitutional Basic, Clinical and Translational Research Projects in Cancer
The Case CCC will provide seed money to foster collaborations and promote and increase institution-wide capacity and competitiveness in basic, clinical or translational research that is aligned with the Cancer Center Scientific Programs and spans the institutions of the Case CCC. 2-3 awards of $75,000 - $100,000 will be made.
Faculty at all levels with interests in cancer research are encouraged to apply. Proposals require a minimum of two PIs: one from Case/UH and one from Cleveland Clinic. Proposals must involve new collaborative work with no joint publications or grants related to the current project. Applications will be submitted through http://webgrants.case.edu.
Deadline: TODAY, January 18, 2011
Complete information is available on the Cancer Center website.
New cancer research protocols requiring IRB review will be submitted, reviewed and stored electronically using the Case Cancer IRB electronic, web-based submission and review database provided by iMedRIS™ Data Corporation.
Part 4 (How to Respond to Stipulations) and Part 5 (How to submit Amendments) of the iMedRIS™ training sessions will be offered January through February. All interactive training will be accessible online using Adobe Acrobat Connect and telephone conference line and can be accessed at personal workstations.
Clinical Assay Development Program (CADP)
The NIH has recently unveiled a new program, the Clinical Assay Development Program (CADP), designed to provide support and expertise to aid in the transition of predictive or prognostic cancer research assays to clinically validated, robust, "CLIA-approved" assays. This program is similar in scope and design to the RAID program for drug development.
The assay to be developed must measure predictive or prognostic markers, assays measuring diagnostic markers will not be considered for this program. The primary biospecimens to be utilized will be archived, formalin fixed, paraffin embedded tissues, however, assays utilizing other biospecimens will be acceptable if they are sufficiently compelling. One important eligibility criterion requires that the assay must be able to be performed with instrumentation and techniques available in standard clinical labs.
The deadline for the first round of applications is January 21.
For additional information or to request assistance in development of an application, please contact: John Pink (email@example.com), Director, Translational Research Core Facility, Case Comprehensive Cancer Center.
Details on the CADP are also available at http://cancer.case.edu/notices/files/CADPInfo.pdf
**All events are open to anyone interested in attending
Martin Luther King Day
Taussig Cancer Institute Core Curriculum Series
Developmental Therapeutics Program meeting canceled
Hematology and Oncology Division Research Conference canceled
11th Annual ASH Review
Department of Immunology Seminar
Special Cancer Center Seminar Series
Taussig Cancer Institute Grand Rounds
Cancer Center Seminar Series
Cell Biology Seminar Series
Cancer Center Research in Progress Seminar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
Breast Cancer Detection and Management: Issues for 2011
8th International Conference of the Society for Integrative Oncology
ADDITIONAL UPCOMING SEMINARS & EVENTS
Active Living Research Annual Conference
14th Annual Meeting of the Translational Research Cancer Centers Consortium 2011
Multilevel Interventions in Health Care: Building the Foundation for Future Research Goals
4th Annual Biospecimen Research Network (BRN) Symposium: Advancing Cancer Research Through Biospecimen Science
2011 Clinical and Translational Research and Education Meeting: ACRT/SCTS Joint Annual Meeting
International Society for Stem Cell Research (ISSCR) Annual Meeting
Cancer Health Disparities Summit 2011
Shared Instrumentation Grant - DEXA Scanner
Message from Dr. Nathan Berger
As part of the Case CCC, we anticipate responding to NIH Shared Instrument Grant (S1O) PAR-11-081 with a request for a Dual-Energy X-ray Absorption (DEXA) Scanner. DEXA Scanning provides state-of-the-art technology for measurement of lean body-muscle mass, fat mass and bone density. We will apply for a patient level instrument and if enough interest exists, we will also apply for an instrument to perform the same measurements in small animals. Policy permitting, we are also considering applying for a Direct Segmental Multi-Frequency Bioelectrical Impedance Apparatus to perform repetitive measurements of body composition.
As you know, these awards are made to support the needs of groups of NIH funded investigators. Accordingly, I am requesting that any NIH funded investigators who anticipate using DEXA Scanning as a research tool notify me of their intent and send to me by January 20 a description of their research and need for these measurements (no more than 1 page), along with name, title and description of relevant NIH grant funding and an updated copy of your biosketch in NIH format. Please send all materials to firstname.lastname@example.org.
Please pass this email along to any other faculty member who might be interested. I would be happy to talk to anyone who wants further clarification.
NCI CANCER BULLETIN
January 11, 2011
PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES
Avon Foundation Breast Cancer Research Program
Leukemia Research Foundation
NIH BULLETIN – Notices and Funding Opportunities
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to email@example.com.